Oncotelic Therapeutics, Inc. (OTLC) shareholders
Close on Oct 19, 2026Market cap $8.66MP/E 0.0Yield –
Ownership
Who owns Oncotelic Therapeutics's shares
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Vuong Trieu | CHAIRMAN AND CEO, Director, 10% owner | 119,134,222 | 26.04% | Oct 30, 2026 |
| Anthony E. Maida Iii | DIRECTOR AND CMO - TRANS. MED. | 1,137,314 | 0.25% | Jul 14, 2026 |
| Seymour Howard Fein | CRO/CMO | – | – | Jul 23, 2026 |
| Saran Saund | CBO | 16,457,480 | 3.60% | Jul 14, 2026 |
| Amit B. Shah | CFO | 378,837 | 0.08% | Jul 14, 2026 |
| Steven W. King | Director | 4,027,351 | 0.88% | Jul 21, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Vuong Trieu CHAIRMAN AND CEO, Director, 10% owner | Oct 29, 2026 | Buy | +1,044,990 | $0.02 | $17.76K | 95,481,309 |
| Vuong Trieu CHAIRMAN AND CEO, Director, 10% owner | Oct 28, 2026 | Buy | +312,000 | $0.02 | $5.77K | 94,436,319 |
| Vuong Trieu CHAIRMAN AND CEO, Director, 10% owner | Jul 1, 2026 | Buy | +240,000 | $0.04 | $9.60K | 94,124,319 |
| Vuong Trieu CHAIRMAN AND CEO, Director, 10% owner | Jun 24, 2026 | Buy | +115,000 | $0.05 | $5.75K | 93,884,319 |
| Vuong Trieu CHAIRMAN AND CEO, Director, 10% owner | Jun 23, 2026 | Buy | +75,000 | $0.05 | $3.75K | 93,769,319 |
| Vuong Trieu CHAIRMAN AND CEO, Director, 10% owner | Jun 22, 2026 | Buy | +65,000 | $0.05 | $3.25K | 93,694,319 |
| Amit B. Shah CFO | Jun 22, 2026 | Buy | +20,000 | $0.05 | $1.00K | 378,837 |
| Vuong Trieu CHAIRMAN AND CEO, Director, 10% owner | Jun 17, 2026 | Buy | +239,759 | $0.04 | $9.59K | 93,629,319 |
| Vuong Trieu CHAIRMAN AND CEO, Director, 10% owner | Jun 15, 2026 | Buy | +96,000 | $0.05 | $4.80K | 93,389,560 |
| Vuong Trieu CHAIRMAN AND CEO, Director, 10% owner | Jul 10, 2025 | Buy | +104,000 | $0.01 | $1.04K | 93,293,560 |
| Vuong Trieu CHAIRMAN AND CEO, Director, 10% owner | Jul 9, 2025 | Buy | +1 | $0.01 | $0 | 93,293,561 |
| Vuong Trieu CHAIRMAN AND CEO, Director, 10% owner | Jul 8, 2025 | Buy | +94,736 | $0.01 | $947 | 93,388,297 |
| Vuong Trieu CHAIRMAN AND CEO, Director, 10% owner | Jan 31, 2025 | Buy | +63,775 | $0.03 | $1.91K | 93,189,560 |
| Vuong Trieu CHAIRMAN AND CEO, Director, 10% owner | Jan 30, 2025 | Buy | +100,003 | $0.03 | $3.00K | 93,125,785 |
| Vuong Trieu CHAIRMAN AND CEO, Director, 10% owner | Jan 29, 2025 | Buy | +183,066 | $0.03 | $5.49K | 93,025,782 |
| Vuong Trieu CHAIRMAN AND CEO, Director, 10% owner | Nov 22, 2024 | Buy | +298,499 | $0.03 | $8.95K | 92,842,716 |
| Vuong Trieu CHAIRMAN AND CEO, Director, 10% owner | Aug 23, 2024 | Buy | +500,000 | $0.02 | $10.00K | 92,544,217 |
| Vuong Trieu CHAIRMAN AND CEO, Director, 10% owner | Jun 29, 2023 | Buy | +425,000 | $0.02 | $8.50K | 92,044,217 |
| Vuong Trieu CHAIRMAN AND CEO, Director, 10% owner | Jun 28, 2023 | Buy | +75,000 | $0.03 | $2.25K | 91,619,217 |
| Vuong Trieu CHAIRMAN AND CEO, Director, 10% owner | Jun 16, 2023 | Buy | +100,000 | $0.03 | $3.00K | 91,544,217 |
| Vuong Trieu CHAIRMAN AND CEO, Director, 10% owner | Jun 14, 2023 | Buy | +400,000 | $0.03 | $12.00K | 91,444,217 |
| Vuong Trieu CHAIRMAN AND CEO, Director, 10% owner | May 26, 2023 | Buy | +126,888 | $0.03 | $3.81K | 91,044,217 |
| Vuong Trieu CHAIRMAN AND CEO, Director, 10% owner | May 2, 2023 | Buy | +100,000 | $0.05 | $5.00K | 90,917,329 |
| Vuong Trieu CHAIRMAN AND CEO, Director, 10% owner | Dec 6, 2022 | Buy | +120,000 | $0.05 | $6.00K | 90,558,021 |
| Vuong Trieu CHAIRMAN AND CEO, Director, 10% owner | Nov 22, 2022 | Buy | +70,000 | $0.08 | $5.60K | 90,438,021 |
| Vuong Trieu CHAIRMAN AND CEO, Director, 10% owner | Sep 26, 2022 | Buy | +20,000 | $0.07 | $1.40K | 90,368,021 |
| Vuong Trieu CHAIRMAN AND CEO, Director, 10% owner | Aug 25, 2022 | Buy | +80,000 | $0.08 | $6.40K | 90,348,021 |
| Vuong Trieu CHAIRMAN AND CEO, Director, 10% owner | Jul 8, 2021 | Award | +259,302 | – | – | 90,527,323 |
| Amit B. Shah CHIEF FINANCIAL OFFICER | Jul 8, 2021 | Award | +298,837 | – | – | 358,837 |
| Saran Saund CHIEF BUSINESS OFFICER | Jul 8, 2021 | Award | +102,519 | – | – | 16,457,480 |
| Anthony E. Maida Iii CHIEF CLINICAL OFFICER, Director | Mar 31, 2021 | Conversion | +938,646 | – | – | 1,137,314 |
| Vuong Trieu CHAIRMAN AND CEO, Director, 10% owner | Mar 31, 2021 | Conversion | +5,672,025 | – | – | 6,872,529 |
| Vuong Trieu CHAIRMAN AND CEO, Director, 10% owner | Mar 31, 2021 | Conversion | +13,849,161 | – | – | 16,780,384 |
| Vuong Trieu CHAIRMAN AND CEO, Director, 10% owner | Mar 31, 2021 | Conversion | +74,455,719 | – | – | 90,268,021 |
| Steven W. King Director | Mar 31, 2021 | Conversion | +3,291,720 | – | – | 3,330,647 |
| Saran Saund CHIEF BUSINESS OFFICER | Mar 31, 2021 | Conversion | +16,354,961 | – | – | 16,354,961 |
| Amit B. Shah CHIEF FINANCIAL OFFICER | Nov 24, 2020 | Buy | +8,220 | $0.19 | $1.56K | 60,000 |
| Amit B. Shah CHIEF FINANCIAL OFFICER | Nov 23, 2020 | Buy | +20,088 | $0.19 | $3.82K | 51,780 |
| Amit B. Shah CHIEF FINANCIAL OFFICER | Nov 20, 2020 | Buy | +31,692 | $0.20 | $6.34K | 31,692 |
| Vuong Trieu CHIEF EXECUTIVE OFFICER | Nov 19, 2020 | Buy | +50,500 | $0.19 | $9.60K | 15,812,308 |
| Chulho Park CHIEF TECHNOLOGY OFFICER | Nov 19, 2020 | Buy | +22,173 | $0.18 | $3.99K | 2,833,992 |
| Vuong Trieu CHIEF EXECUTIVE OFFICER | Mar 26, 2020 | Buy | +3,000 | $0.12 | $360 | 15,761,808 |
| Matthew M. Loar Chief Financial Officer | Apr 12, 2018 | Buy | +250,000 | – | – | 300,000 |
| Donald Rogers Reynolds Director | Apr 12, 2018 | Buy | +250,000 | – | – | 280,000 |
| William D. Schwieterman President and CEO, Director | Apr 12, 2018 | Buy | +625,000 | – | – | 625,747 |
| Donald Rogers Reynolds Director | Dec 16, 2016 | Buy | +12,700 | $0.34 | $4.32K | 12,700 |
| Donald Rogers Reynolds Director | Dec 16, 2016 | Buy | +9,950 | $0.36 | $3.58K | 30,000 |
| Donald Rogers Reynolds Director | Dec 16, 2016 | Buy | +7,350 | $0.35 | $2.57K | 20,050 |
| Gerald McMahon PhD Director | Jul 2, 2014 | Award | +3,847 | – | – | 18,611 |
| Gerald McMahon PhD Director | Jan 2, 2014 | Award | +3,584 | – | – | 14,764 |
| Peter Langecker Chief Executive Officer, Director | Aug 8, 2013 | Award | +72,993 | – | – | 77,993 |
| Gerald McMahon PhD Director | Jul 1, 2013 | Award | +7,407 | – | – | 11,180 |
| Tamar D. Howson Director | Jul 1, 2013 | Award | +3,703 | – | – | 8,761 |
| Peter Langecker Chief Executive Officer, Director | Jun 28, 2013 | Buy | +3,000 | $2.75 | $8.25K | 5,000 |
| Peter Langecker Chief Executive Officer, Director | Jun 25, 2013 | Buy | +2,000 | $2.79 | $5.58K | 2,000 |
| Tamar D. Howson Director | Jan 2, 2013 | Award | +1,886 | – | – | 5,058 |
| Gerald McMahon PhD Director | Jan 2, 2013 | Award | +3,773 | – | – | 3,773 |
| Tamar D. Howson Director | Jul 2, 2012 | Award | +18,148 | – | – | 38,060 |
| Tamar D. Howson Director | Jul 1, 2012 | Award | +18,148 | – | – | 38,060 |
| Tamar D. Howson Director | Jan 2, 2012 | Award | +10,101 | – | – | 19,912 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Oncotelic Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 12 shares on Sep 17, 2026 over the last 90 days.
See a number that looks wrong?